IndiaCOVID-19Ministry of Health and Family WelfareHealth

COVID – 19 Vaccination Update – Day 393

India’s cumulative vaccination coverage crosses 172.75Crore. More than 44 lakh Vaccine doses administered today till 7 pm

India’s COVID-19 vaccination coverage has crossed172.75 Crore (172,75,94,539today. More than 44lakh (44,63,682Vaccine Doseshave been administered till 7 pm today. More than1.72 Crore(1,72,02,866) Precaution Doses for the identified categories of beneficiaries (HCWs, FLWs and Over 60 years) for COVID vaccination have been administered so far. The daily vaccination tally is expected to increase with the compilation of the final reports for the day by late tonight.

The cumulative coverage of vaccine doses, segregated based on population priority groups, is as follows:

Cumulative Vaccine Dose Coverage
HCWs 1st Dose 10399379
2nd Dose 9930159
Precaution Dose 3876145
FLWs 1st Dose 18405049
2nd Dose 17373764
Precaution Dose 5344760
Age Group 15-18 years 1st Dose 51987388
2nd Dose 14694234
Age Group 18-44 years 1st Dose 547971374
2nd Dose 426140948
Age Group 45-59 years 1st Dose 201603878
2nd Dose 176224094
Over 60 years 1st Dose 125869357
2nd Dose 109792049
Precaution Dose 7981961
Cumulative 1st dose administered 956236425
Cumulative 2nd dose administered 754155248
Precaution Dose 17202866
Total 1727594539

 

Today’s achievement in the vaccination exercise, segregated by population priority groups, is as follows:

Date: 12th February, 2022 (393rdDay)
HCWs 1st Dose 216
2nd Dose 4041
Precaution Dose 31800
FLWs 1st Dose 466
2nd Dose 7449
Precaution Dose 88877
Age Group 15-18 years 1st Dose 296271
2nd Dose 1250989
Age Group 18-44 years 1st Dose 439149
2nd Dose 1467037
Age Group 45-59 years 1st Dose 92232
2nd Dose 319863
Over 60 years 1st Dose 65696
2nd Dose 202863
Precaution Dose 196733
Cumulative 1st dose administered 894030
Cumulative 2nd dose administered 3252242
Precaution Dose 317410
Total 4463682

 

The vaccination exercise as a tool to protect the most vulnerable population groups in the country from COVID-19 continues to be regularly reviewed and monitored at the highest level.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Comment moderation is enabled. Your comment may take some time to appear.

Back to top button